Cummins

The journey of energy transition which we are all in is not an easy one. There is not one answer that suits all. As the energy transition becomes a higher priority, we can explore key ways in which we can prepare ourselves to navigate the energy future. 

Explore more videos from our series ‘The Future of Energy [simplified]’ – a video series that provides answers to your most frequently asked questions about the energy transition.

About Cummins Inc.

Cummins Inc., a global power solutions leader, is comprised of five business segments – Components, Engine, Distribution, Power Systems and Accelera by Cummins – supported by our global manufacturing and extensive service and support network, skilled workforce and vast technological expertise. Cummins is committed to its Destination Zero strategy, which is grounded in the company’s commitment to sustainability and helping its customers successfully navigate the energy transition with its broad portfolio of products. The products range from advanced diesel, natural gas, electric and hybrid powertrains and powertrain-related components including filtration, aftertreatment, turbochargers, fuel systems, valvetrain technologies, controls systems, air handling systems, automated transmissions, axles, drivelines, brakes, suspension systems, electric power generation systems, batteries, electrified power systems, hydrogen production technologies and fuel cell products. Headquartered in Columbus, Indiana (U.S.), since its founding in 1919, Cummins employs approximately 75,500 people committed to powering a more prosperous world through three global corporate responsibility priorities critical to healthy communities: education, environment and equality of opportunity. Cummins serves its customers online, through a network of company-owned and independent distributor locations, and through thousands of dealer locations worldwide and earned about $735 million on sales of $34.1 billion in 2023. See how Cummins is powering a world that’s always on by accessing news releases and more information at https://www.cummins.com/.

© 2024 Cummins Inc. All rights reserved.

Las Vegas Sands

As part of Women’s History Month 2024, Sands recently welcomed Cynt Marshall, CEO of the Dallas Mavericks, as a guest speaker for the In Focus DEI Conversation Series, which provides corporate Team Members with perspectives from diverse leaders in the corporate, nonprofit and public sectors.

With the same majority shareholder ownership, the Dallas Mavericks and Sands enjoy a “first cousin” relationship, as Marshall and series leader and moderator Ron Reese, chair of the company’s diversity, equity and inclusion (DEI) council, discussed during the session.

Sands invited Marshall to share her journey to assuming one of the top leadership positions in professional basketball and her work to build inclusiveness in a top sports organization and corporate America

Marshall drew on stories from her 2022 book, “You’ve Been Chosen: Thriving Through the Unexpected,” which chronicles her journey in overcoming a turbulent childhood, overt and subtle racism in her career, and a life-threatening battle with cancer. Like the book, the In Focus session exuded the effervescent positive outlook and deep wisdom Marshall cultivated through these experiences and her enduring faith.

Marshall joined the Dallas Mavericks as CEO in 2018. Though she was the first Black woman to become a CEO in the National Basketball Association – a milestone that should have been widely celebrated – her appointment on the heels of diversity issues in the Mavericks’ organization brought more skepticism around her ability to succeed than accolades.

Yet, under Marshall’s leadership, the Dallas Mavericks organization has become an award-winning, best-in-class operation – marking another challenge she overcame.

Marshall brought extensive leadership experience to the Mavericks, particularly in the area of DEI. Before joining the team, she served in a variety of positions, including as chief diversity officer, with AT&T during her 36-year tenure. After leaving AT&T, she founded her own consulting company to guide corporate clients on DEI issues and organizational change.

Marshall had been working with a leading global corporate client to develop and implement a strategy for institutionalizing an inclusive culture when Mavericks owner Mark Cuban called about an “opportunity.” Originally intending to turn it down, the chance to make an impact in changing organizational culture was too enticing to pass up.

“He (Cuban) told me, ‘I need a leader. I need someone who could transform cultures.’ I went home, prayed about it, talked to a lot of different people and just said, yes. I just felt called to do it … even though I didn’t know the business of basketball. He told me don’t worry about that. He told me his request was to create a great place to work. Together, we laid out a vision and a set of values.”

With this roadmap, the Dallas Mavericks organization continues to set the standard for workplace culture, innovation and corporate social responsibility, and is a two-time recipient of the NBA’s Inclusion Leadership award.

Marshall and Reese kicked off the In Focus session by discussing the value of observances such as Women’s History Month and Black History Month.

“Women and Black people have contributed a lot to this country and to this world,” Marshall said. “We don’t always recognize the amazing contributions of these groups of people … These months are an opportunity to appreciate just the richness and diversity of the people who make this country great.”

Marshall talked about facing career challenges as she was often the first woman, the first Black person or the first Black woman in a role. From pressure to change her appearance to the way she spoke, Marshall complied in the early years of her career. At one pivotal point, however, she took a stand.

On the cusp of becoming an officer at AT&T, she was told she had to change her hair and name (because what is the name Cynt, she was told) and lower her speaking voice when she assumed the position.

“So when it got to that point, I just told (the hiring leader) … I feel like you’re fundamentally trying to change who I am,” Marshall said. “And I actually knew that wasn’t the company that I worked for – but that’s where she was going with it, so I turned it down.”

Marshall’s commitment to authenticity paid off. After a call from the chairman of AT&T, she officially accepted.

“He said, ‘Let’s start all over again. I know exactly who you are.’ And he described me to a tee. He said, ‘That’s the person who we want to walk into our doors as an officer tomorrow.’ And he gave me this great pep talk. And then he offered me the job again. And I said yes. And I love to tell that story.”

Marshall relayed the experience as an example of strong leadership and recognizing the value of authenticity and diversity.

“I like that story because it shows the powerful words of a leader, and how a leader can actually free somebody into being themselves, which is what we all want,” she said. “We want people to walk in the door as their authentic self every day and give us the best of what they have to offer.

“That’s one of our values at the Mavericks, along with character, respect, authenticity, fairness, teamwork and safety, both physical and emotional safety. That’s why the authenticity piece is so important to me, because somebody gave me the okay to be me and to bring my full self to work.”

When Marshall began the challenging work of turning around the Mavericks organization, she relied on the vision of leadership she formed in witnessing and practicing great leadership.

“It’s simple for me; it’s three Ls,” Marshall said. “If I want to be an effective leader, I need to do these three things: listen to the people, learn from the people and love the people. And that’s what I did, I listened to these people. I met with every single employee in the first 90 days. I just wanted to know who they were. I wanted to learn from them. I wanted to get to know them and love them as people.”

Beyond the three Ls, the turnaround required deep organizational changes, including upheaval in the leadership team.

“We had no women in permanent leadership positions, or people of color. We very quickly formed a diverse group of people.”

She shared the success of these changes as a call to action for all companies. “We need women at the table we’re on. If you want to get it right, you need to have everybody at the table, including women. My team is 50% women now. I’m very, very proud of that.”

Through all of the challenging experiences Marshall has faced in her life and career, three things have been her sustaining strengths: her faith, her family and having purpose.

“I am a woman who is driven by purpose,” she said. “And I believe that I am here for a purpose. And there are some things that I need to get done to fulfill my mission on this Earth. I believe that for all of us. I’m very optimistic because the way I describe it – I have receipts.

“My husband is battling cancer right now. And he just had a stem cell transplant a couple of weeks ago. And I remain optimistic because I have receipts. I got through domestic violence as a child. I got through my dad breaking my nose. I got through four second-trimester miscarriages, and a daughter who died at six months, and the Lord blessed us to adopt four amazing kids, three of them totally abandoned, abused and neglected.

“And I look at their stories and what they’ve gone through – those are my receipts. I’ve gone through cancer myself. My husband had brain damage. And they said he would never walk or talk again. He’s 95% back to normal. I just know it’s going to work out, somehow that God and great people always, always show up. I don’t hide what’s important to me. I know it’s all going to work out. So that’s what I do.”

The In Focus DEI Conversation Series for Sands corporate Team Members is one of the company’s core DEI programs, which aim to build a collaborative and integrated environment in the workplace and at the company’s resorts by removing systemic barriers and creating opportunities for underrepresented groups.

For more information on the company’s DEI initiatives, read the latest ESG report: https://www.sands.com/resources/reports/.

Organizing large-scale music festivals is often associated with significant environmental challenges. Festivals can generate massive amounts of waste, from attendees discarding single use-items like plastic cups and food containers, to emitting high levels of Co2 emissions from the generators powering each stage.

AEG’s Goldenvoice is challenging convention by pioneering sustainable practices in festival organizing and utilizing its three-day music festival in Long Beach, CA, Cali Vibes, as a blueprint for greening their own festival operations.

Now for the second consecutive year, Goldenvoice’s Cali Vibes, has partnered with Three Squares Inc., a Los Angeles-based environmental consulting firm, to develop a comprehensive sustainability program aimed at reducing emissions, minimizing waste, educating attendees and staff, and fostering eco-friendly practices throughout its operations.

Welcoming 25,000 fans per day, Cali Vibes allowed sustainability to take the main stage by adopting the following green initiatives:

Food Waste Reduction – All extra food at the festival was donated to local community shelters. Additionally, roughly 20% to 30% of the food vendors at Cali Vibes provided vegan menu options, with all vendors required to offer at least one vegetarian option.Reusable Cup Program: Through its partnership with r.World, the festival utilized r.Cup reusable cups and eliminated approximately 300,000 single-use plastic cups. Water was served in aluminum cans, and refill stations were located throughout the festival.Reducing Energy: To reduce on site energy consumption, Cali Vibes sourced Overdrive Energy Solutions’ battery power stations to capture solar energy to power light towers in parking lots, merch stations and bathroom zones. Energy efficient lighting systems relied on battery-powered LED lights. By sourcing locally-produced renewable diesel to power generators and heavy equipment, Cali Vibes eliminated 43 tons of carbon emissions at this year’s festival.Reducing Emissions: The festival promoted public transit use by offering attendees free or discounted public transit rides through a partnership with L.A. Metro. Festival organizers also implemented a “no idling” rule to reduce emissions by requiring cars and gas-powered golf carts to be turned off when not in motion.

In addition to greening its festival operations, the team at Goldenvoice partnered with AEG’s Social Impact department to nurture the next generation of environmental stewards by hosting an AEG Futures event at the festival. The career program brought together [50] underrepresented high school and college students to learn about sustainability-focused career opportunities available in live entertainment. The program offered students a chance to learn from industry experts about career opportunities, meet sustainability vendors who spoke to them about the specific Cali Vibes initiatives, participate in mentoring sessions, and explore the festival grounds, fostering a deeper understanding of sustainable practices in the live music space.

CNH recently welcomed the UK’s Italian Ambassador, Inigo Lambertini, along with the Director of the London Office ITA – Italian Trade Agency, Mr. Giovanni Sacchi and the Italian diplomatic delegation at the company’s plant in Basildon, Essex, a center of excellence for alternative fuel technology. Institutional stakeholders were welcomed by Andrea Paulis, CNH Group Treasurer & Head of EMEA Institutional Relations, Sean Lennon, Vice President New Holland Agriculture Europe and Mike Simpson, Chief Executive – Bennamann and CNH Ag. Renewable Energy Leader. 

The institutional visit was an opportunity to discuss the company’s net zero farming vision, where biomethane plays a key role, and to deep dive into their range of sustainable technologies and advanced agricultural machinery, such as the New Holland Agriculture T6 Methane Power.

This year the Basildon plant celebrates 60 years of manufacturing, an ideal time for the Ambassador and his delegation to get to grips with CNH’s latest innovations.

With the Ambassador’s visit, CNH upholds its firm commitment to sustainable innovation for farming, whether in Essex, or around the globe.

CNH recently welcomed the UK’s Italian Ambassador, Inigo Lambertini, along with the Director of the London Office ITA – Italian Trade Agency, Mr. Giovanni Sacchi and the Italian diplomatic delegation at the company’s plant in Basildon, Essex, a center of excellence for alternative fuel technology. Institutional stakeholders were welcomed by Andrea Paulis, CNH Group Treasurer & Head of EMEA Institutional Relations, Sean Lennon, Vice President New Holland Agriculture Europe and Mike Simpson, Chief Executive – Bennamann and CNH Ag. Renewable Energy Leader. 

The institutional visit was an opportunity to discuss the company’s net zero farming vision, where biomethane plays a key role, and to deep dive into their range of sustainable technologies and advanced agricultural machinery, such as the New Holland Agriculture T6 Methane Power.

This year the Basildon plant celebrates 60 years of manufacturing, an ideal time for the Ambassador and his delegation to get to grips with CNH’s latest innovations.

With the Ambassador’s visit, CNH upholds its firm commitment to sustainable innovation for farming, whether in Essex, or around the globe.

NEW YORK, April 23, 2024 /3BL/ – The National Diversity Council (NDC) and Tri-State Diversity Council (TSDC) will host its annual National Asian American Native Hawaiian & Pacific Islander (AANHPI) Leadership Summit on Tuesday, March 28, 2024 from 10:30 a.m.-2:30 p.m. ET at New York Life Insurance, 51 Madison Avenue, New York, NY 10010. The 2024 Women in Leadership Symposium theme, “Advancing AANHPI Leadership: Value, Virtue & Visibility,” will bring together AANHPI leaders who will help educate, inspire and empower attendees to reflect on their own personal and professional goals.

“We must continue to highlight the values and virtues of AANHPI leaders, while emphasizing the intersections of identity, resilience and strength in redefining power within the AANHPI community,” said Emily Pfister, Event Programmer of the Tri-State Diversity Council. “We invite you to join us for the National Asian American Native Hawaiian & Pacific Islander Leadership Summit as we discuss best-practices for inclusion and belonging.”

The conference will feature emcee, Lucy Yang, Television Reporter, American Broadcasting Company (ABC) and panelists, Gurwin Ahuja, Vice President, BlackRock; Melissa Chiu, Director, Hirshhorn Museum and Sculpture Garden; Thomas J. Lee CFA, Co-founder/Managing Partner and Head of Research, Fundstrat Global Advisors; and Ripa Rashid, Chief Diversity & Inclusion Officer, Consumer Reports. The featured keynote speaker is BD Wong, Actor/Public Figure of Viking Entertainment. The conference will also recognize the following Top AANHPI Leader awardees: Gurwin Ahuja, Vice President, BlackRock; Melissa Chiu, Director, Hirshhorn Museum and Sculpture Garden, Priya Udeshi Crick, Associate General Counsel, Office of the General Council, New York Life Insurance; and BD Wong, Actor/Public Figure, Viking Entertainment.

The event sponsor includes PSCU. To learn more information about the event visit

https://tristatediversitycouncil.org/events/2024-asian-american-pacific-islander-leadership-summit/ or for sponsorship opportunities, please contact Emily Pfister at emily.pfister@nationaldiversitycouncil.org.

About the National Diversity Council

The National Diversity Council (NDC) is a 501 (c) (3) organization dedicated to being both a resource and an advocate for the value of diversity, equity, inclusion and belonging (DEIB). Through our nationwide affiliates, events and learning and consulting, the NDC helps organizations create pathways that develop a more inclusive workplace, community and environment. For more information about the National Diversity Council, please visit www.nationaldiversitycouncil.org.

About the Tri-State Diversity Council 

The Tri-State Diversity Council (TSDC), a state affiliate of the National Diversity Council, is committed to fostering diversity, equity, inclusion and belonging. Through various events and programs, the TSDC serves as a resource for DEIB best practices and leadership development in the Tri-State region. For more information about the Tri-State Diversity Council, please visit https://tristatediversitycouncil.org/.

Media Contact: Kamaria Monmouth

Sr. Communications Specialist
National Diversity Council
kamaria.monmouth@nationaldiversitycouncil.org

###

NEW YORK, April 23, 2024 /3BL/ – The National Diversity Council (NDC) and Tri-State Diversity Council (TSDC) will host its annual National Asian American Native Hawaiian & Pacific Islander (AANHPI) Leadership Summit on Tuesday, March 28, 2024 from 10:30 a.m.-2:30 p.m. ET at New York Life Insurance, 51 Madison Avenue, New York, NY 10010. The 2024 Women in Leadership Symposium theme, “Advancing AANHPI Leadership: Value, Virtue & Visibility,” will bring together AANHPI leaders who will help educate, inspire and empower attendees to reflect on their own personal and professional goals.

“We must continue to highlight the values and virtues of AANHPI leaders, while emphasizing the intersections of identity, resilience and strength in redefining power within the AANHPI community,” said Emily Pfister, Event Programmer of the Tri-State Diversity Council. “We invite you to join us for the National Asian American Native Hawaiian & Pacific Islander Leadership Summit as we discuss best-practices for inclusion and belonging.”

The conference will feature emcee, Lucy Yang, Television Reporter, American Broadcasting Company (ABC) and panelists, Gurwin Ahuja, Vice President, BlackRock; Melissa Chiu, Director, Hirshhorn Museum and Sculpture Garden; Thomas J. Lee CFA, Co-founder/Managing Partner and Head of Research, Fundstrat Global Advisors; and Ripa Rashid, Chief Diversity & Inclusion Officer, Consumer Reports. The featured keynote speaker is BD Wong, Actor/Public Figure of Viking Entertainment. The conference will also recognize the following Top AANHPI Leader awardees: Gurwin Ahuja, Vice President, BlackRock; Melissa Chiu, Director, Hirshhorn Museum and Sculpture Garden, Priya Udeshi Crick, Associate General Counsel, Office of the General Council, New York Life Insurance; and BD Wong, Actor/Public Figure, Viking Entertainment.

The event sponsor includes PSCU. To learn more information about the event visit

https://tristatediversitycouncil.org/events/2024-asian-american-pacific-islander-leadership-summit/ or for sponsorship opportunities, please contact Emily Pfister at emily.pfister@nationaldiversitycouncil.org.

About the National Diversity Council

The National Diversity Council (NDC) is a 501 (c) (3) organization dedicated to being both a resource and an advocate for the value of diversity, equity, inclusion and belonging (DEIB). Through our nationwide affiliates, events and learning and consulting, the NDC helps organizations create pathways that develop a more inclusive workplace, community and environment. For more information about the National Diversity Council, please visit www.nationaldiversitycouncil.org.

About the Tri-State Diversity Council 

The Tri-State Diversity Council (TSDC), a state affiliate of the National Diversity Council, is committed to fostering diversity, equity, inclusion and belonging. Through various events and programs, the TSDC serves as a resource for DEIB best practices and leadership development in the Tri-State region. For more information about the Tri-State Diversity Council, please visit https://tristatediversitycouncil.org/.

Media Contact: Kamaria Monmouth

Sr. Communications Specialist
National Diversity Council
kamaria.monmouth@nationaldiversitycouncil.org

###

Abbott

Just a week before the pro football draft, Abbott held a high-profile draft day experience for our HeartMates program. Hosted by Abbott, professional football player and heart health advocate Damar Hamlin and Tedy Bruschi, a three-time pro league champion, Abbott HeartMates Draft Day recognized 11 people and their caregivers from across the United States who have come back from serious cardiovascular conditions and made them official members of the Abbott HeartMates team.

Hamlin and Bruschi know a thing or two about comebacks – as well as the importance of heart health and having support from a team. When Hamlin experienced a cardiac event during a game in 2023, his teammates, family and medical team had his back like true MVPs. And in 2005, Bruschi experienced a stroke caused by a hole in his heart. After receiving an Abbott Amplatzer device, he was able to rejoin his team just months later and was named the 2005 Comeback Player of the Year.

“Draft Day was one of the most exciting and memorable days of my life,” Hamlin said. “Today I am inspired by the amazing bravery and resilience of each of the Abbott HeartMates and hope they feel just as I did on the day I was drafted.”

“Anyone can be impacted by a heart condition,” Bruschi said. “That’s why it is so important to not only raise awareness about the signs and symptoms of heart disease, stroke and other ailments, but also share diverse stories of survivor comeback journeys.”

The celebration kicked off at the New York Stock Exchange, where draftees joined Hamlin and cardiovascular experts from Abbott on the trading-floor podium to ring the iconic opening bell. Later in the day, HeartMates and their guests, along with Abbott employees and media, gathered at a special venue for a one-of-a-kind event that captured the excitement and ceremony of a professional sports draft.

Hamlin and Bruschi introduced each Heartmate from the stage, telling the story of how they discovered their heart condition and what it took for them to make their comeback. In practically every case, the support and sense of community each person received from their team of family members, friends and medical professionals were significant factors in spurring their recovery.

After being recognized onstage, each HeartMate received a personalized team jersey and signed a contract in which they committed to inspiring others with their stories.

“Our HeartMates reflect a broad scope of the population impacted by cardio conditions,” said Nadim Geloo, M.D., senior director of medical affairs in Abbott’s Structural Heart business. “We have HeartMates who are experiencing heart failure and are on the list to receive a heart transplant, those who were born with holes in their hearts that didn’t close on the own, and people from many backgrounds and age ranges. Their stories offer hope and solidarity to so many people around the country and the world.”

The inaugural Abbott HeartMates team includes the following heart-health champions.

Michael Brafi, a college football player from Woodbury, N.Y., experienced sudden cardiac arrest similar to Hamlin but caused by a previously undiagnosed heart defect. Brafi met Hamlin at a HeartMates event at his hospital, and the two bonded over their shared experience.

Lakeisha Brown, a wife and mother of four daughters and owner of a catering business in Houston, started experiencing discomfort in her chest in 2018. After seeing several doctors and receiving a pacemaker defibrillator, her condition continued to deteriorate into heart failure. Brown received a HeartMate 3 Left Ventricular Assist Device (LVAD) and is now back to living her life to the fullest.

Tony Daly, aka “Little Tony,” lives in Las Vegas. As a premature infant born at 26 weeks and six days, he was the first person to receive Abbott’s Amplatzer Piccolo Occluder to close a hole in his heart. Thanks to this life-saving procedure, Daly is now thriving and loves tennis, soccer and excels at school.

Chris Donges of Wilmington, Del., experienced heart failure when he was 30 years old. After a prolonged hospital stay that included a medically induced coma, he received a HeartMate 3 LVAD. Donges will be marrying his long-time fiancé Meghan in October, whom he was dating at the time, and the couple has two young children.

Brody Lambert, a father of four with his own construction company and a small farm in Provo, Utah, has overcome several conditions, undergone a heart transplant and has a HeartMate II LVAD. Most recently, Lambert was enrolled in the clinical trial for the TriClip G4 system, Abbott’s minimally invasive device for repairing leaky tricuspid valves, which was approved by the FDA in early April.

MacKenzie Maddry has overcome a lot in her 17 years. Diagnosed with osteosarcoma at age 14, Maddry underwent 21 cycles of chemotherapy. This intense treatment, coupled with multiple surgeries and infections, put her cancer in remission but led to heart failure. Maddry received a HeartMate 3 LVAD device in 2022 and was the first pediatric patient discharged from her hospital with an LVAD. She has since returned to her high school studies in Bella Vista, Ark., had another leg reconstruction surgery and is looking forward to being listed for a heart transplant.

Ezekiel “Zeke” Mankins was first Abbott HeartMates draftee and was featured on NBC Nightly News. At age 12 Mankins had open heart surgery and received an Abbott Masters mechanical heart valve to repair a leaking mitral valve, and he’s now a star on his high school track team in Midlothian, Texas. He is also an accomplished trombonist and aspiring pilot.

Alicia Nicoletti was in a car accident at age 22 that severely injured her heart and eventually lead to heart failure. In 2021, Nicoletti was implanted with the CardioMEMS HF System that allows her medical team to remotely monitor her pulmonary artery pressure and intervene if necessary. Now almost 20 years after her accident, Nicoletti is living in Wantagh, N.Y., successfully managing her heart failure and educating others about the condition.

Karen Pekowitz is a mother and teacher from Wellesley, Mass., who received her first pacemaker when she was just 19 years old. Earlier this year she became the first person in Massachusetts to receive an AVEIR DR, the world’s first dual chamber leadless pacemaker system.

Leonardo Rodriguez grew up in New York City and enjoyed all it had to offer – but not always with heart health in mind. Rodriguez developed heart disease in his early 50s and received his first stent at age 54. Taking his doctor’s advice to heart, he immediately adopted healthier habits and has a new lease on life.

Seth Wharton of LaVale, Md., had his first heart surgery, necessary to treat his severe aortic stenosis, when he was just 1 month old. After a battery of additional operations and treatments, Wharton went on to become a college basketball player, a father of four and a Guinness World Record holder for the longest survivor of an artificial double heart valve replacement – both of which were Abbott valves.

About Abbott HeartMates

The Abbott HeartMates program celebrates the bravery in those with cardiovascular conditions, the teams of families, friends and caregivers who support them, and the heroes providing the medical care need to help people make their comeback. By creating a community in which members can share stories, connect with others going through similar heart-health journeys and receive emotional support, Abbott and program ambassador Damar Hamlin hope to inspire people and ensure that no one faces these health challenges alone. Rounding out the team is a lineup of Abbott cardio experts to provide knowledge and resources in language that’s easy to understand.

Throughout the year, Hamlin and Abbott will visit hospitals around the country to recruit new HeartMates, host virtual huddles and share exclusive content that’s only available to teammates.

For more information about HeartMates, visit HeartMates.Abbott.

IMPORTANT SAFETY INFORMATION

CARDIOMEMS™ HF SYSTEM

AVEIR™ DR

AMPLATZER PICCOLOTM OCCLUDER

Rx Only

The Amplatzer Piccolo™ Occluder is a percutaneous, transcatheter occlusion device intended for the nonsurgical closure of a patent ductus arteriosus (PDA).

CONTRAINDICATIONS

Weight < 700 grams at time of the procedure; Age < 3 days at time of procedure; Coarctation of the aorta; Left pulmonary artery stenosis; Cardiac output that is dependent on right to left shunt through the PDA due to pulmonary hypertension; Intracardiac thrombus that may interfere with the implant procedure; Active infection requiring treatment at the time of implant; Patients with a PDA length smaller than 3 mm; Patients with a PDA diameter that is greater than 4 mm at the narrowest portion.

POTENTIAL ADVERSE EVENTS

Potential adverse events that may occur during or after a procedure using this device may include, but are not limited to: Air embolus, Allergic reaction, Anemia, Anesthesia reactions, Apnea, Arrhythmia, Bleeding, Cardiac perforation, Cardiac tamponade, Chest pain, Device embolization, Device erosion, Death, Endocarditis, Fever, Headache/migraine, Hemolysis, Hematoma, Hypertension, Hypotension, Infection, Myocardial infarction, Palpitations, Partial obstruction of aorta, Partial obstruction of pulmonary artery, Pericardial effusion, Pericarditis, Peripheral embolism, Pleural effusion, Pulmonary embolism, Re-intervention for device removal, Respiratory distress, Stroke, Thrombus, Transient ischemic attack, Valvular regurgitation, Vascular access site injury, Vascular occlusion, Vessel perforation.

HEARTMATE 3

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions For Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications: The HeartMate 3 Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

Adverse Events: Adverse events that may be associated with the use of the HeartMate 3™ Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.

HEARTMATE II LVAD

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions For Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications: The HeartMate II™ Left Ventricular Assist System is indicated for use as a “bridge to transplantation” for cardiac transplant candidates who are at risk of imminent death from non-reversible left ventricle failure. It is also indicated for use in patients with New York Heart Association (NYHA) Class IIIB or IV end-stage left ventricular failure, who have received optimal medical therapy for at least 45 of the last 60 days, and who are not candidates for cardiac transplantation. The HeartMate II Left Ventricular Assist System is intended for use both inside and outside of the hospital, or for transportation of Left Ventricular Assist Device patients via ground ambulance, airplane, or helicopter.

Contraindications: The HeartMate II Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulationtherapy.

Adverse Events: Adverse events that may be associated with the use of the HeartMate II Left Ventricular Assist System are listed below. Adverse events are listed in decreasing order of frequency, except for death, which appears first because it is a non-reversible complication:Death, Bleeding (perioperative or late), Cardiac arrhythmia, Local infection, Respiratory failure, Device malfunction, Sepsis, Right heart failure, Driveline or pump pocket infection, Renal failure, Stroke, Neurologic dysfunction, Psychiatric episode, Peripheral thromboembolic event, Hemolysis, Hepatic dysfunction, Device thrombosis, Myocardial infarction.

TRICLIP™ G4 SYSTEM

Rx Only

INDICATIONS

The TriClip™ G4 System is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.

CONTRAINDICATIONS

The TriClip G4 System is contraindicated in patients with the following conditions: Intolerance, including allergy or untreatable hypersensitivity, to procedural anticoagulation; Untreatable hypersensitivity to implant components (nickel-titanium alloy, cobalt-chromium alloy); Active endocarditis or other active infection of the tricuspid valve. POTENTIAL

ADVERSE EVENTS

The following events have been identified as possible complications of the TriClip™ G4 Procedure. Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials and drug reactions to anticoagulation, or antiplatelet drugs; Additional treatment / surgery from device-related complications; Bleeding; Blood disorders (including coagulopathy, hemolysis, and Heparin Induced Thrombocytopenia (HIT)); Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias); Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, and unstable / stable angina); Cardiac perforation; Cardiac tamponade; Chest pain; Death; Dyspnea; Edema; Embolization (device or components of the device); Endocarditis; Fever or hyperthermia; Fluoroscopy, Transesophageal echocardiogram (TEE) and Transthoracic echocardiogram (TTE) -related complications: Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation, Esophageal perforation, Gastrointestinal bleeding; Hypotension / hypertension; Infection including: Septicemia; Nausea / vomiting; Pain; Pericardial effusion; Stroke / Cerebrovascular accident (CVA) and Transient Ischemic Attack (TIA); System organ failure: Cardio-respiratory arrest, Worsening heart failure, Pulmonary congestion, Respiratory dysfunction / failure / atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic); Thrombosis; Tricuspid valve complications, which may complicate or prevent later surgical repair, including: Chordal entanglement / rupture, Single Leaflet Device Attachment (SLDA), Dislodgement of previously implanted devices, Tissue damage, Tricuspid valve stenosis, Worsening, Persistent or residual regurgitation; Vascular access complications which may require additional intervention, including: Wound dehiscence, Bleeding of the access site, Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation / rupture, vascular occlusion, Embolism (air, thrombus), Peripheral nerve injury; Venous thromboembolism (including deep vein thrombosis, pulmonary embolism). CAUTION: Product(s) intended for use by or under the direction of a physician. Prior to use, reference to the Instructions for Use, inside the product carton (when available) or at https://www.eifu.abbott/ for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

MASTERS SERIES MECHANICAL HEART VALVE

Rx Only

Indications for Use

The SJM™ Masters Series Mechanical Heart Valve is intended for use as a replacement valve in patients with a diseased, damaged, or malfunctioning aortic or mitral heart valve. This device may also be used to replace a previously implanted mitral or aortic prosthetic valve.

Contraindications

The SJM™ Masters Series Mechanical Heart Valve is contraindicated for individuals unable to tolerate anticoagulation therapy.

Potential Adverse Events

Complications associated with replacement mechanical heart valves include, but are not limited to, hemolysis, infections, thrombus, or thromboembolism, valve dehiscence, unacceptable hemodynamic performance, hemorrhagic complications secondary to anticoagulation therapy, prosthetic failure, failure or death. Any of these complications may require reoperation or explantation of the device.

CARDIOMEMS™ HF SYSTEM

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

CardioMEMS™ HF System Indications and Usage: The CardioMEMS HF System is indicated for wirelessly measuring and monitoring pulmonary artery pressure and heart rate in NYHA Class II or III heart failure patients who either have been hospitalized for heart failure in the previous year and/or have elevated natriuretic peptides. The hemodynamic data are used by physicians for heart failure management with the goal of controlling pulmonary artery pressures and reducing heart failure hospitalizations.

CardioMEMS HF System Contraindications: The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

CardioMEMS HF System Adverse Events: Potential adverse events associated with the implantation procedure include, but are not limited to, the following: air embolism, allergic reaction, infection, delayed wound healing, arrhythmias, bleeding, hemoptysis, hematoma, nausea, cerebrovascular accident, thrombus, cardiovascular injury, myocardial infarction, death, embolization, thermal burn, cardiac perforation, pneumothorax, thoracic duct injury and hemothorax.

myCardioMEMS™ Mobile App Limitations: Patients must use their own Apple‡ or Android‡ mobile device to receive and transmit information to the myCardioMEMS Mobile App. To do so the device must be powered on, app must be installed and data coverage (cellular or Wi-Fi‡) available. The myCardioMEMS App can provide notification of medication adjustments and reminders, requests for lab work and acknowledgement that the PA pressure readings have been received. However there are many internal and external factors that can hinder, delay, or prevent acquisition and delivery of the notifications and patient information as intended by the clinician. These factors include: patient environment, data services, mobile device operating system and settings, clinic environment, schedule/configuration changes, or data processing.

AVEIR™ DR

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications: The Aveir™ Leadless Pacemaker system is indicated for management of one or more of the following permanent conditions: Syncope, Pre-syncope, Fatigue, Disorientation. Rate-modulated pacing is indicated for patients with chronotropic incompetence, and for those who would benefit from increased stimulation rates concurrent with physical activity. Dual-chamber pacing is indicated for patients exhibiting: Sick sinus syndrome, Chronic, symptomatic second- and third-degree AV block, Recurrent Adams-Stokes syndrome, Symptomatic bilateral bundle-branch block when tachyarrhythmia and other causes have been ruled out. Atrial pacing is indicated for patients with: Sinus node dysfunction and normal AV and intraventricular conduction systems. Ventricular pacing is indicated for patients with: Significant bradycardia and normal sinus rhythm with only rare episodes of AV block or sinus arrest, Chronic atrial fibrillation, Severe physical disability.

Intended Use: The Aveir™ Leadless Pacemaker (LP) is designed to provide bradycardia pacing as a pulse generator with built-in battery and electrodes for implantation in the right ventricle and/or right atrium. The LP is intended to provide sensing of intrinsic cardiac signals and delivery of cardiac pacing therapy within the implanted chamber for the target treatment group. The LP is also intended to operate optionally with another co-implanted LP to provide dual-chamber pacing therapy.

The Aveir™ Delivery Catheter is intended to be used in the peripheral vasculature and the cardiovascular system to deliver and manipulate an LP. Delivery and manipulation includes implanting an LP within the target chamber of the heart.

Contraindications: Use of the Aveir™ Leadless Pacemaker is contraindicated in these cases:

Use of any pacemaker is contraindicated in patients with a co-implanted ICD because high-voltage shocks could damage the pacemaker and the pacemaker could reduce shock effectiveness.Single-chamber ventricular demand pacing is relatively contraindicated in patients who have demonstrated pacemaker syndrome, have retrograde VA conduction, or suffer a drop in arterial blood pressure with the onset of ventricular pacing.Programming of rate-responsive pacing is contraindicated in patients with intolerance of high sensor driven rates.Use is contraindicated in patients with an implanted vena cava filter or mechanical tricuspid valve because of interference between these devices and the delivery system during implantation.Persons with known history of allergies to any of the components of this device may suffer an allergic reaction to this device. Prior to use on the patient, the patient should be counseled on the materials (listed in the Product Materials section of the IFU) contained in the device and a thorough history of allergies must be discussed.

Adverse Events: Potential complications associated with the use of the Aveir™ Leadless Pacemaker system are the same as with the use of single or dual chamber pacemakers with active fixation pacing leads including, but not limited to: Cardiac perforation, Cardiac tamponade, Pericardial effusion, Pericarditis, Valve damage and/or regurgitation, Heart failure, Pneumothorax/hemothorax, Cardiac arrhythmias, Diaphragmatic/phrenic nerve stimulation / extra-cardiac stimulation, Palpitations, Hypotension, Syncope, Cerebrovascular accident, Infection, Hypersensitivity reaction to device materials, contrast media, medications, or direct toxic effect of contrast media on kidney function, Pacemaker syndrome, Inability to interrogate or program the LP due to programmer or LP malfunction, Intermittent or complete loss of pacing and/or sensing due to dislodgement or mechanical malfunction of the LP (non-battery related), Loss of capture or sensing due to embolization or fibrotic tissue response at the electrode, Increased capture threshold, Inappropriate sensor response, Interruption of desired LP function due to electrical interference, either electromyogenic or electromagnetic, Battery malfunction/ premature battery depletion, Device-related complications (Premature deployment, Device dislodgement/embolization of foreign material, Helix distortion), Death. As with any percutaneous catheterization procedure, potential complications include, but are not limited to: Vascular access complications; such as perforation, dissection, puncture, groin pain, Bleeding or hematoma, Thrombus formation, Thromboembolism, Air embolism, Local and systemic infection, Peripheral nerve damage. General surgery risks and complications from comorbidities; such as hypotension, dyspnea, respiratory failure, syncope, pneumonia, hypertension, cardiac failure, reaction to sedation, renal failure, anemia, and death.

MAT-2306873 v1.0 | Item is approved for US Use

Abbott

Just a week before the pro football draft, Abbott held a high-profile draft day experience for our HeartMates program. Hosted by Abbott, professional football player and heart health advocate Damar Hamlin and Tedy Bruschi, a three-time pro league champion, Abbott HeartMates Draft Day recognized 11 people and their caregivers from across the United States who have come back from serious cardiovascular conditions and made them official members of the Abbott HeartMates team.

Hamlin and Bruschi know a thing or two about comebacks – as well as the importance of heart health and having support from a team. When Hamlin experienced a cardiac event during a game in 2023, his teammates, family and medical team had his back like true MVPs. And in 2005, Bruschi experienced a stroke caused by a hole in his heart. After receiving an Abbott Amplatzer device, he was able to rejoin his team just months later and was named the 2005 Comeback Player of the Year.

“Draft Day was one of the most exciting and memorable days of my life,” Hamlin said. “Today I am inspired by the amazing bravery and resilience of each of the Abbott HeartMates and hope they feel just as I did on the day I was drafted.”

“Anyone can be impacted by a heart condition,” Bruschi said. “That’s why it is so important to not only raise awareness about the signs and symptoms of heart disease, stroke and other ailments, but also share diverse stories of survivor comeback journeys.”

The celebration kicked off at the New York Stock Exchange, where draftees joined Hamlin and cardiovascular experts from Abbott on the trading-floor podium to ring the iconic opening bell. Later in the day, HeartMates and their guests, along with Abbott employees and media, gathered at a special venue for a one-of-a-kind event that captured the excitement and ceremony of a professional sports draft.

Hamlin and Bruschi introduced each Heartmate from the stage, telling the story of how they discovered their heart condition and what it took for them to make their comeback. In practically every case, the support and sense of community each person received from their team of family members, friends and medical professionals were significant factors in spurring their recovery.

After being recognized onstage, each HeartMate received a personalized team jersey and signed a contract in which they committed to inspiring others with their stories.

“Our HeartMates reflect a broad scope of the population impacted by cardio conditions,” said Nadim Geloo, M.D., senior director of medical affairs in Abbott’s Structural Heart business. “We have HeartMates who are experiencing heart failure and are on the list to receive a heart transplant, those who were born with holes in their hearts that didn’t close on the own, and people from many backgrounds and age ranges. Their stories offer hope and solidarity to so many people around the country and the world.”

The inaugural Abbott HeartMates team includes the following heart-health champions.

Michael Brafi, a college football player from Woodbury, N.Y., experienced sudden cardiac arrest similar to Hamlin but caused by a previously undiagnosed heart defect. Brafi met Hamlin at a HeartMates event at his hospital, and the two bonded over their shared experience.

Lakeisha Brown, a wife and mother of four daughters and owner of a catering business in Houston, started experiencing discomfort in her chest in 2018. After seeing several doctors and receiving a pacemaker defibrillator, her condition continued to deteriorate into heart failure. Brown received a HeartMate 3 Left Ventricular Assist Device (LVAD) and is now back to living her life to the fullest.

Tony Daly, aka “Little Tony,” lives in Las Vegas. As a premature infant born at 26 weeks and six days, he was the first person to receive Abbott’s Amplatzer Piccolo Occluder to close a hole in his heart. Thanks to this life-saving procedure, Daly is now thriving and loves tennis, soccer and excels at school.

Chris Donges of Wilmington, Del., experienced heart failure when he was 30 years old. After a prolonged hospital stay that included a medically induced coma, he received a HeartMate 3 LVAD. Donges will be marrying his long-time fiancé Meghan in October, whom he was dating at the time, and the couple has two young children.

Brody Lambert, a father of four with his own construction company and a small farm in Provo, Utah, has overcome several conditions, undergone a heart transplant and has a HeartMate II LVAD. Most recently, Lambert was enrolled in the clinical trial for the TriClip G4 system, Abbott’s minimally invasive device for repairing leaky tricuspid valves, which was approved by the FDA in early April.

MacKenzie Maddry has overcome a lot in her 17 years. Diagnosed with osteosarcoma at age 14, Maddry underwent 21 cycles of chemotherapy. This intense treatment, coupled with multiple surgeries and infections, put her cancer in remission but led to heart failure. Maddry received a HeartMate 3 LVAD device in 2022 and was the first pediatric patient discharged from her hospital with an LVAD. She has since returned to her high school studies in Bella Vista, Ark., had another leg reconstruction surgery and is looking forward to being listed for a heart transplant.

Ezekiel “Zeke” Mankins was first Abbott HeartMates draftee and was featured on NBC Nightly News. At age 12 Mankins had open heart surgery and received an Abbott Masters mechanical heart valve to repair a leaking mitral valve, and he’s now a star on his high school track team in Midlothian, Texas. He is also an accomplished trombonist and aspiring pilot.

Alicia Nicoletti was in a car accident at age 22 that severely injured her heart and eventually lead to heart failure. In 2021, Nicoletti was implanted with the CardioMEMS HF System that allows her medical team to remotely monitor her pulmonary artery pressure and intervene if necessary. Now almost 20 years after her accident, Nicoletti is living in Wantagh, N.Y., successfully managing her heart failure and educating others about the condition.

Karen Pekowitz is a mother and teacher from Wellesley, Mass., who received her first pacemaker when she was just 19 years old. Earlier this year she became the first person in Massachusetts to receive an AVEIR DR, the world’s first dual chamber leadless pacemaker system.

Leonardo Rodriguez grew up in New York City and enjoyed all it had to offer – but not always with heart health in mind. Rodriguez developed heart disease in his early 50s and received his first stent at age 54. Taking his doctor’s advice to heart, he immediately adopted healthier habits and has a new lease on life.

Seth Wharton of LaVale, Md., had his first heart surgery, necessary to treat his severe aortic stenosis, when he was just 1 month old. After a battery of additional operations and treatments, Wharton went on to become a college basketball player, a father of four and a Guinness World Record holder for the longest survivor of an artificial double heart valve replacement – both of which were Abbott valves.

About Abbott HeartMates

The Abbott HeartMates program celebrates the bravery in those with cardiovascular conditions, the teams of families, friends and caregivers who support them, and the heroes providing the medical care need to help people make their comeback. By creating a community in which members can share stories, connect with others going through similar heart-health journeys and receive emotional support, Abbott and program ambassador Damar Hamlin hope to inspire people and ensure that no one faces these health challenges alone. Rounding out the team is a lineup of Abbott cardio experts to provide knowledge and resources in language that’s easy to understand.

Throughout the year, Hamlin and Abbott will visit hospitals around the country to recruit new HeartMates, host virtual huddles and share exclusive content that’s only available to teammates.

For more information about HeartMates, visit HeartMates.Abbott.

IMPORTANT SAFETY INFORMATION

CARDIOMEMS™ HF SYSTEM

AVEIR™ DR

AMPLATZER PICCOLOTM OCCLUDER

Rx Only

The Amplatzer Piccolo™ Occluder is a percutaneous, transcatheter occlusion device intended for the nonsurgical closure of a patent ductus arteriosus (PDA).

CONTRAINDICATIONS

Weight < 700 grams at time of the procedure; Age < 3 days at time of procedure; Coarctation of the aorta; Left pulmonary artery stenosis; Cardiac output that is dependent on right to left shunt through the PDA due to pulmonary hypertension; Intracardiac thrombus that may interfere with the implant procedure; Active infection requiring treatment at the time of implant; Patients with a PDA length smaller than 3 mm; Patients with a PDA diameter that is greater than 4 mm at the narrowest portion.

POTENTIAL ADVERSE EVENTS

Potential adverse events that may occur during or after a procedure using this device may include, but are not limited to: Air embolus, Allergic reaction, Anemia, Anesthesia reactions, Apnea, Arrhythmia, Bleeding, Cardiac perforation, Cardiac tamponade, Chest pain, Device embolization, Device erosion, Death, Endocarditis, Fever, Headache/migraine, Hemolysis, Hematoma, Hypertension, Hypotension, Infection, Myocardial infarction, Palpitations, Partial obstruction of aorta, Partial obstruction of pulmonary artery, Pericardial effusion, Pericarditis, Peripheral embolism, Pleural effusion, Pulmonary embolism, Re-intervention for device removal, Respiratory distress, Stroke, Thrombus, Transient ischemic attack, Valvular regurgitation, Vascular access site injury, Vascular occlusion, Vessel perforation.

HEARTMATE 3

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions For Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications: The HeartMate 3 Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

Adverse Events: Adverse events that may be associated with the use of the HeartMate 3™ Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.

HEARTMATE II LVAD

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions For Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications: The HeartMate II™ Left Ventricular Assist System is indicated for use as a “bridge to transplantation” for cardiac transplant candidates who are at risk of imminent death from non-reversible left ventricle failure. It is also indicated for use in patients with New York Heart Association (NYHA) Class IIIB or IV end-stage left ventricular failure, who have received optimal medical therapy for at least 45 of the last 60 days, and who are not candidates for cardiac transplantation. The HeartMate II Left Ventricular Assist System is intended for use both inside and outside of the hospital, or for transportation of Left Ventricular Assist Device patients via ground ambulance, airplane, or helicopter.

Contraindications: The HeartMate II Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulationtherapy.

Adverse Events: Adverse events that may be associated with the use of the HeartMate II Left Ventricular Assist System are listed below. Adverse events are listed in decreasing order of frequency, except for death, which appears first because it is a non-reversible complication:Death, Bleeding (perioperative or late), Cardiac arrhythmia, Local infection, Respiratory failure, Device malfunction, Sepsis, Right heart failure, Driveline or pump pocket infection, Renal failure, Stroke, Neurologic dysfunction, Psychiatric episode, Peripheral thromboembolic event, Hemolysis, Hepatic dysfunction, Device thrombosis, Myocardial infarction.

TRICLIP™ G4 SYSTEM

Rx Only

INDICATIONS

The TriClip™ G4 System is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.

CONTRAINDICATIONS

The TriClip G4 System is contraindicated in patients with the following conditions: Intolerance, including allergy or untreatable hypersensitivity, to procedural anticoagulation; Untreatable hypersensitivity to implant components (nickel-titanium alloy, cobalt-chromium alloy); Active endocarditis or other active infection of the tricuspid valve. POTENTIAL

ADVERSE EVENTS

The following events have been identified as possible complications of the TriClip™ G4 Procedure. Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials and drug reactions to anticoagulation, or antiplatelet drugs; Additional treatment / surgery from device-related complications; Bleeding; Blood disorders (including coagulopathy, hemolysis, and Heparin Induced Thrombocytopenia (HIT)); Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias); Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, and unstable / stable angina); Cardiac perforation; Cardiac tamponade; Chest pain; Death; Dyspnea; Edema; Embolization (device or components of the device); Endocarditis; Fever or hyperthermia; Fluoroscopy, Transesophageal echocardiogram (TEE) and Transthoracic echocardiogram (TTE) -related complications: Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation, Esophageal perforation, Gastrointestinal bleeding; Hypotension / hypertension; Infection including: Septicemia; Nausea / vomiting; Pain; Pericardial effusion; Stroke / Cerebrovascular accident (CVA) and Transient Ischemic Attack (TIA); System organ failure: Cardio-respiratory arrest, Worsening heart failure, Pulmonary congestion, Respiratory dysfunction / failure / atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic); Thrombosis; Tricuspid valve complications, which may complicate or prevent later surgical repair, including: Chordal entanglement / rupture, Single Leaflet Device Attachment (SLDA), Dislodgement of previously implanted devices, Tissue damage, Tricuspid valve stenosis, Worsening, Persistent or residual regurgitation; Vascular access complications which may require additional intervention, including: Wound dehiscence, Bleeding of the access site, Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation / rupture, vascular occlusion, Embolism (air, thrombus), Peripheral nerve injury; Venous thromboembolism (including deep vein thrombosis, pulmonary embolism). CAUTION: Product(s) intended for use by or under the direction of a physician. Prior to use, reference to the Instructions for Use, inside the product carton (when available) or at https://www.eifu.abbott/ for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

MASTERS SERIES MECHANICAL HEART VALVE

Rx Only

Indications for Use

The SJM™ Masters Series Mechanical Heart Valve is intended for use as a replacement valve in patients with a diseased, damaged, or malfunctioning aortic or mitral heart valve. This device may also be used to replace a previously implanted mitral or aortic prosthetic valve.

Contraindications

The SJM™ Masters Series Mechanical Heart Valve is contraindicated for individuals unable to tolerate anticoagulation therapy.

Potential Adverse Events

Complications associated with replacement mechanical heart valves include, but are not limited to, hemolysis, infections, thrombus, or thromboembolism, valve dehiscence, unacceptable hemodynamic performance, hemorrhagic complications secondary to anticoagulation therapy, prosthetic failure, failure or death. Any of these complications may require reoperation or explantation of the device.

CARDIOMEMS™ HF SYSTEM

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

CardioMEMS™ HF System Indications and Usage: The CardioMEMS HF System is indicated for wirelessly measuring and monitoring pulmonary artery pressure and heart rate in NYHA Class II or III heart failure patients who either have been hospitalized for heart failure in the previous year and/or have elevated natriuretic peptides. The hemodynamic data are used by physicians for heart failure management with the goal of controlling pulmonary artery pressures and reducing heart failure hospitalizations.

CardioMEMS HF System Contraindications: The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

CardioMEMS HF System Adverse Events: Potential adverse events associated with the implantation procedure include, but are not limited to, the following: air embolism, allergic reaction, infection, delayed wound healing, arrhythmias, bleeding, hemoptysis, hematoma, nausea, cerebrovascular accident, thrombus, cardiovascular injury, myocardial infarction, death, embolization, thermal burn, cardiac perforation, pneumothorax, thoracic duct injury and hemothorax.

myCardioMEMS™ Mobile App Limitations: Patients must use their own Apple‡ or Android‡ mobile device to receive and transmit information to the myCardioMEMS Mobile App. To do so the device must be powered on, app must be installed and data coverage (cellular or Wi-Fi‡) available. The myCardioMEMS App can provide notification of medication adjustments and reminders, requests for lab work and acknowledgement that the PA pressure readings have been received. However there are many internal and external factors that can hinder, delay, or prevent acquisition and delivery of the notifications and patient information as intended by the clinician. These factors include: patient environment, data services, mobile device operating system and settings, clinic environment, schedule/configuration changes, or data processing.

AVEIR™ DR

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications: The Aveir™ Leadless Pacemaker system is indicated for management of one or more of the following permanent conditions: Syncope, Pre-syncope, Fatigue, Disorientation. Rate-modulated pacing is indicated for patients with chronotropic incompetence, and for those who would benefit from increased stimulation rates concurrent with physical activity. Dual-chamber pacing is indicated for patients exhibiting: Sick sinus syndrome, Chronic, symptomatic second- and third-degree AV block, Recurrent Adams-Stokes syndrome, Symptomatic bilateral bundle-branch block when tachyarrhythmia and other causes have been ruled out. Atrial pacing is indicated for patients with: Sinus node dysfunction and normal AV and intraventricular conduction systems. Ventricular pacing is indicated for patients with: Significant bradycardia and normal sinus rhythm with only rare episodes of AV block or sinus arrest, Chronic atrial fibrillation, Severe physical disability.

Intended Use: The Aveir™ Leadless Pacemaker (LP) is designed to provide bradycardia pacing as a pulse generator with built-in battery and electrodes for implantation in the right ventricle and/or right atrium. The LP is intended to provide sensing of intrinsic cardiac signals and delivery of cardiac pacing therapy within the implanted chamber for the target treatment group. The LP is also intended to operate optionally with another co-implanted LP to provide dual-chamber pacing therapy.

The Aveir™ Delivery Catheter is intended to be used in the peripheral vasculature and the cardiovascular system to deliver and manipulate an LP. Delivery and manipulation includes implanting an LP within the target chamber of the heart.

Contraindications: Use of the Aveir™ Leadless Pacemaker is contraindicated in these cases:

Use of any pacemaker is contraindicated in patients with a co-implanted ICD because high-voltage shocks could damage the pacemaker and the pacemaker could reduce shock effectiveness.Single-chamber ventricular demand pacing is relatively contraindicated in patients who have demonstrated pacemaker syndrome, have retrograde VA conduction, or suffer a drop in arterial blood pressure with the onset of ventricular pacing.Programming of rate-responsive pacing is contraindicated in patients with intolerance of high sensor driven rates.Use is contraindicated in patients with an implanted vena cava filter or mechanical tricuspid valve because of interference between these devices and the delivery system during implantation.Persons with known history of allergies to any of the components of this device may suffer an allergic reaction to this device. Prior to use on the patient, the patient should be counseled on the materials (listed in the Product Materials section of the IFU) contained in the device and a thorough history of allergies must be discussed.

Adverse Events: Potential complications associated with the use of the Aveir™ Leadless Pacemaker system are the same as with the use of single or dual chamber pacemakers with active fixation pacing leads including, but not limited to: Cardiac perforation, Cardiac tamponade, Pericardial effusion, Pericarditis, Valve damage and/or regurgitation, Heart failure, Pneumothorax/hemothorax, Cardiac arrhythmias, Diaphragmatic/phrenic nerve stimulation / extra-cardiac stimulation, Palpitations, Hypotension, Syncope, Cerebrovascular accident, Infection, Hypersensitivity reaction to device materials, contrast media, medications, or direct toxic effect of contrast media on kidney function, Pacemaker syndrome, Inability to interrogate or program the LP due to programmer or LP malfunction, Intermittent or complete loss of pacing and/or sensing due to dislodgement or mechanical malfunction of the LP (non-battery related), Loss of capture or sensing due to embolization or fibrotic tissue response at the electrode, Increased capture threshold, Inappropriate sensor response, Interruption of desired LP function due to electrical interference, either electromyogenic or electromagnetic, Battery malfunction/ premature battery depletion, Device-related complications (Premature deployment, Device dislodgement/embolization of foreign material, Helix distortion), Death. As with any percutaneous catheterization procedure, potential complications include, but are not limited to: Vascular access complications; such as perforation, dissection, puncture, groin pain, Bleeding or hematoma, Thrombus formation, Thromboembolism, Air embolism, Local and systemic infection, Peripheral nerve damage. General surgery risks and complications from comorbidities; such as hypotension, dyspnea, respiratory failure, syncope, pneumonia, hypertension, cardiac failure, reaction to sedation, renal failure, anemia, and death.

MAT-2306873 v1.0 | Item is approved for US Use

This Earth Month, M·A·C Cosmetics was proud to visit VIVA GLAM grantee Plastics for Change in Mangalore, India to learn about their recycling efforts and give back to the local community. The trip was to drive awareness around the organization and the expansion of VIVA GLAM’s charitable mission as part of its 30th anniversary, which now includes supporting organizations working towards environmental equality.

Plastics for Change is a trusted source of fair trade-verified recycled plastic and aims to reduce plastic waste from our planet. M·A·C began its partnership with the organization last year, with an initial donation of $100,000 which enabled the collection of over 550,000 pounds of plastic (equivalent to 12,500,000 plastic bottles) from the coast of India while supporting approximately 200 plastic collectors and their communities with a host of social services for one year.

While in India, the M·A·C team volunteered with the local community alongside M·A·C India’s VIVA GLAM Ambassador, Bhumi Pednekar, participating in beach cleanups, collecting waste on E-tricycles, and helping sort plastics at the Plastics for Change recycling facility. The team also had the opportunity to meet incredible local scrap shop owners, including three women entrepreneurs who run their own scrap shops with the support of M·A·C VIVA GLAM’s grant.

The trip also served as an employee engagement opportunity for M·A·C Artists who are committed to the M·A·C VIVA GLAM philanthropic campaign. In January, the brand launched an Artist Challenge to the brand’s 13,000 makeup artists around the globe, with Artists tasked to create content on their social channels sharing why they are passionate about M·A·C VIVA GLAM. Five Artists were ultimately selected as the winners – check out their inspiring winning entries below:

APAC (New Zealand): Adrian Josephs [watch winning entry]LATAM (Argentina): Maximiliano Muñoz [watch winning entry]UK & IRELAND: Hannah McLean [watch winning entry]EMEA (Netherlands): Hannah Bennett [watch winning entry]INDIA: Adarsh Mishra [watch winning entry]

M·A·C was proud to see first-hand how VIVA GLAM grantee partner Plastics for Change is working towards better livelihoods and a cleaner planet and shared a recap of the trip on the brand’s social channels for Earth Day. You can help support organizations like Plastics for Change by purchasing a M·A·C VIVA GLAM Lipstick – the Lipstick that Gives Back 100%.

Learn more about VIVA GLAM here

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.